Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or 2) metastatic disease.~* HER2 positive disease (3+ by immunohistochemistry \[IHC\] or FISH-positive)~* Candidate for treatment with trastuzumab. Prior treatment with trastuzumab and or/ lapatinib in the neoadjuvant, adjuvant or metastatic disease setting is permitted. Treatment with hormone therapy in the adjuvant and/or advanced disease setting is permitted.~Exclusion Criteria:~* Prior treatment with \>1 regimen of cytotoxic therapy in the advanced disease setting. Adjuvant chemotherapy is permitted~* Prior exposure to trastuzumab if the patient had developed severe hypersensitivity reactions.~* Prior treatment on a SU11248 clinical trial.~* Uncontrolled brain metastases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).